Clinical Trials
임상시험 트래커
국내사는 전체 임상 이력, 글로벌 메이저는 진행 중 파이프라인을 추적합니다. ClinicalTrials.gov API v2에서 6시간 주기로 수집합니다.
기업
60 results (top 60)
- 3상모집 예정· Bladder Cancer방광암 환자에 대한 사시투주맙 티루모테칸(Sac-TMT, MK-2870)과 펨브롤리주맙(MK-3475A) 임상시험(MK-2870-055)
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)
리드: 머크(MSD)
- 3상모집 예정· Hyperlipidemia인도에서 고지혈증 성인 환자에서 엔리시티드(MK-0616)에 대한 임상 연구(MK-0616-038)
A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)
리드: 머크(MSD)
- 3상모집 예정· Papillomavirus Infections이가 HPV 백신 접종 과거력이 있는 중국 여성을 대상으로 한 V503 임상 연구(V503-108)
A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)
리드: 머크(MSD)
- 3상모집 예정· Ovarian CancerPARP억제제 1차 유지요법 중 진행된 난소암 환자에서 라루도타투그 드룩스테칸 ± 베바시주맙 임상시험
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
리드: 머크(MSD)
- 3상모집 예정· Fallopian Tube Cancer2차 백금민감성 재발성 난소암 유지 요법에서 라루도타투그 데룩스테칸(R-DXd)의 베바시주맙 병용 여부 평가 연구(REJOICE-Ovarian03)
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
협력: 머크(MSD)
- 3상모집 예정· Diabetic Retinopathy당뇨병성 황반부종 환자에서 MK-8748과 아플리버셉트 비교 임상시험(MK-8748-005)
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
리드: 머크(MSD)
- 3상모집 예정· Ovarian CancerHRD 음성 진행성 난소암에서 라루도타투그 더룩스테칸 단독 또는 베바시주맙 병용을 1차 유지 치료로 하는 연구(MK-5909-006, ENGOT-ov102/GOG-3141/REJOICE-Ovarian 04)
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
리드: 머크(MSD)
- 3상모집 중· Diabetic Retinopathy당뇨병성 황반부종 환자에서 MK-8748과 애플리버셉트 비교 임상시험 (MK-8748-004)
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
리드: 머크(MSD)
- 3상모집 중· Colorectal Cancer분자적 잔존 질환이 있는 대장암 환자에서 잔잔린티닙 단독 또는 펨브롤리주맙 및 베라히알루로니다제 알파와의 병용 투여
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
협력: 머크(MSD)
- 3상모집 중· Non-small Cell Lung Cancer비소세포폐암 환자를 대상으로 한 칼데라시브(MK-1084)와 두르발루맙 임상시험 (MK-1084-015/KANDLELIT-015)
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
리드: 머크(MSD)
- 3상모집 중· Non-small Cell Lung CancerV940-014: 완전절제 고위험 1기 비소세포폐암 대상 Intismeran 보조요법 임상시험
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
리드: 머크(MSD) · 협력: 모더나
- 3상모집 중· Bladder Cancer요로상피암 치료를 위한 사시투주맙 티루모테칸(Sac-TMT, MK-2870) 임상시험(MK-2870-031)
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
리드: 머크(MSD)
- 3상모집 중· Carcinoma, Renal Cell신세포암종 환자 대상 벨주티판과 잔잘린티닙 임상시험
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
리드: 머크(MSD)
- 3상모집 중· Von Hippel-Lindau DiseaseExtension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
리드: 머크(MSD)
- 3상모집 중· Non-small Cell Lung CancerMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
리드: 머크(MSD)
- 3상모집 중· Ovarian NeoplasmsA Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
리드: 머크(MSD)
- 3상모집 중· Renal Cell CarcinomaA Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
리드: 머크(MSD)
- 3상모집 중단 (진행 중)· HyperlipidemiaA Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
리드: 머크(MSD)
- 3상모집 중· Human Immunodeficiency Virus (HIV)A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
리드: 머크(MSD)
- 3상모집 중· Non-small Cell Lung CancerStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
협력: 머크(MSD)
- 3상모집 중· Non-small Cell Lung CancerA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
리드: 머크(MSD)
- 3상모집 중단 (진행 중)· Human Immunodeficiency Virus (HIV)A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
리드: 머크(MSD)
- 3상모집 중· Breast NeoplasmsA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
리드: 머크(MSD)
- 3상모집 중· Colon AdenocarcinomaA Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
리드: 머크(MSD)
- 3상모집 중· Breast NeoplasmsA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
리드: 머크(MSD)
- 3상모집 중단 (진행 중)· HealthyA Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)
리드: 머크(MSD)
- 3상모집 중· Oligometastatic Squamous Cell Carcinoma of the Head and NeckPembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
협력: 머크(MSD)
- 3상모집 중· Prostate CancerA Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
리드: 머크(MSD)
- 3상모집 중· Esophageal Squamous Cell CarcinomaA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
협력: 머크(MSD)
- 3상모집 중단 (진행 중)· Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
협력: 머크(MSD)
- 3상모집 중· Diffuse Large B-Cell LymphomaA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
리드: 머크(MSD)
- 3상모집 중· Coronavirus Disease (COVID-19)A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
리드: 머크(MSD)
- 3상모집 중· Carcinoma, Non-Small-Cell LungA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
리드: 머크(MSD) · 협력: 모더나
- 3상모집 중· Triple Negative Breast CancerNeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
협력: 길리어드, 머크(MSD)
- 3상모집 중단 (진행 중)· HIV-1-infectionStudy to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
리드: 길리어드 · 협력: 머크(MSD)
- 3상모집 중단 (진행 중)· HIV-1-InfectionStudy to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
리드: 길리어드 · 협력: 머크(MSD)
- 3상모집 중· Cytomegalovirus InfectionsLetermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
협력: 머크(MSD)
- 3상모집 중단 (진행 중)· HypercholesterolemiaOpen-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
리드: 머크(MSD)
- 3상모집 중단 (진행 중)· Essential ThrombocythemiaBomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
리드: 머크(MSD)
- 3상모집 중· Triple-Negative Breast CancerSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
리드: 머크(MSD)
- 3상모집 중단 (진행 중)· Non-small Cell Lung Cancer (NSCLC)Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
리드: 머크(MSD)
- 3상모집 중· Non-small Cell Lung CancerPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
리드: 머크(MSD)
- 3상모집 중· Neuromuscular BlocksSugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial
협력: 머크(MSD)
- 3상모집 중· Thrombocythemia, EssentialA Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
리드: 머크(MSD)
- 3상모집 중· Small Cell Lung CancerA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
협력: 머크(MSD)
- 3상모집 중단 (진행 중)· Gastroesophageal CancerA Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
리드: 머크(MSD)
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.